Friday, 16 Nov 2018

You are here

'These Results Are Astonishing': What We Heard at ACR 2018

"If radiation was a drug that could improve survival in the metastatic setting like that it would be millions and millions of dollars." -- James B. Yu, of Yale Cancer Center, discussing aggressive use of stereotactic body radiation therapy in oligometastatic cancer.


"Here is a severe, frustrating autoimmune disease where patients improved and have remained off DMARDs for over a decade." -- Keith Sullivan, MD, of Duke University Medical Center in Durham, North Carolina, on hematopoietic stem cell transplantation in scleroderma.


"I think this work truly exemplifies the shifting paradigm towards hypofractionation in prostate cancer..." -- Neha Vapiwala, MD, PhD, of the University of Pennsylvania, on radiotherapy that was as effective as longer-course standard treatments for prostate cancer.


"It is quite popular amongst the frail." -- Murray Brunt, MD, of University Hospitals of North Midlands and Keele University in England, on short-course radiation therapy (RT) and long-term data confirming the safety of weekly hypofractionated RT in early breast cancer.


"The real aim of our treatment now needs to be very much focused on preventing that first recurrence, which occurs in 70% of patients." -- Jonathan Ledermann, MD, of University College London, on upfront maintenance therapy with PARP inhibitor olaparib (Lynparza) for newly diagnosed, advanced BRCA-positive ovarian cancer.


"These results will have a major impact for practice, because we have to implement genomic testing for breast cancer." -- Fabrice Andre, MD, of Institute Gustave Roussy in Villejuif, France, on the PI3K inhibitor alpelisib for advanced hormone receptor-positive breast cancer associated with PIK3CA mutations. 


"Drug development has been very bittersweet in lupus." -- Susan Manzi, MD, of the Lupus Center of Excellence, Allegheny Health Network in Pittsburgh, on ustekinumab's (Stelara) clinical benefits for systemic lupus erythematosus (SLE) through 1 year. 


"This study uproots 40 years of clinical practice and took over 15 years from the time we started this line of inquiry to get to this point in discovery." -- E. Wesley Ely, MD, MPH, of Vanderbilt University Medical Center in Nashville, on a trial of antipsychotics for delirium in ICU patients.  


"The Trump administration is choosing to protect pharma's monopolies over saving lives." -- Robert Weissman, president of Public Citizen, on the administration's failure to address a request for the authorization of generic competition for opioid overdose antidotes such as naloxone (Narcan and Evzio). 


"These results are astonishing." -- Roy Fleischmann, MD, of the University of Texas Southwestern Medical Center in Dallas, on the outcomes of a phase IIb study of the monoclonal antibody bimekizumab for psoriatic arthritis presented in a late-breaker session at the annual meeting of the American College of Rheumatology.

Add new comment

More Like This

The RheumNow Podcast – Heartbreak of Methotrexate (11.16.18)

Dr. Jack Cush reviews the news from the past week at

MMWR: Death by Firearms

The CDC's Morbidity and Mortality Weekly Report (MMWR) reports that during 2015–2016 there was a total of 27,394 firearm homicides and 44,955 firearm suicides among US residents, with 12% and 5% of events occuring in children 10–19 years.

RheumNow Weekly Podcast – 3 Wiseguy Rheumatologists (11.9.18)

Dr Jack Cush reviews the News and Journal reports from the past week on  Be sure to check out our upcoming meeting in March 2019 - RheumNow Live.

E/M Guidelines: Right Road, Wrong Direction

Last July, the Centers for Medicare & Medicaid Services (CMS) proposed new E/M guidelines for office visits with physicians. It issued the final guidelines on November 1, with a few tweaks. Implementation was delayed until 2021 (from 2019), possibly due to overwhelming opposition from physicians.

RheumNow Week in Review – The Heart Attack Report (11.2.18)

Dr Jack Cush reviews the news and journal reports from the past week on